JP2023532046A5 - - Google Patents

Info

Publication number
JP2023532046A5
JP2023532046A5 JP2022580315A JP2022580315A JP2023532046A5 JP 2023532046 A5 JP2023532046 A5 JP 2023532046A5 JP 2022580315 A JP2022580315 A JP 2022580315A JP 2022580315 A JP2022580315 A JP 2022580315A JP 2023532046 A5 JP2023532046 A5 JP 2023532046A5
Authority
JP
Japan
Application number
JP2022580315A
Other languages
Japanese (ja)
Other versions
JP2023532046A (ja
JPWO2021263134A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039139 external-priority patent/WO2021263134A1/en
Publication of JP2023532046A publication Critical patent/JP2023532046A/ja
Publication of JP2023532046A5 publication Critical patent/JP2023532046A5/ja
Publication of JPWO2021263134A5 publication Critical patent/JPWO2021263134A5/ja
Pending legal-status Critical Current

Links

JP2022580315A 2020-06-26 2021-06-25 組換え修飾線維芽細胞増殖因子およびそれを使用した治療 Pending JP2023532046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044980P 2020-06-26 2020-06-26
US63/044,980 2020-06-26
PCT/US2021/039139 WO2021263134A1 (en) 2020-06-26 2021-06-25 Recombinant modified fibroblast growth factors and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2023532046A JP2023532046A (ja) 2023-07-26
JP2023532046A5 true JP2023532046A5 (https=) 2024-07-02
JPWO2021263134A5 JPWO2021263134A5 (https=) 2024-07-02

Family

ID=79281929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580315A Pending JP2023532046A (ja) 2020-06-26 2021-06-25 組換え修飾線維芽細胞増殖因子およびそれを使用した治療

Country Status (6)

Country Link
US (1) US20240024421A1 (https=)
EP (1) EP4172351A4 (https=)
JP (1) JP2023532046A (https=)
KR (1) KR20230066318A (https=)
CN (1) CN116710568A (https=)
WO (1) WO2021263134A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
TWI865835B (zh) * 2020-11-16 2024-12-11 雅祥生技醫藥股份有限公司 穩定的酸性纖維母細胞生長因子組合物
US20230022990A1 (en) * 2021-05-14 2023-01-26 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
WO2023019218A1 (en) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
AU2024247068A1 (en) * 2023-03-28 2025-10-16 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN116392441B (zh) * 2023-04-21 2023-11-28 上海腾瑞制药股份有限公司 一种酸性成纤维细胞生长因子滴眼液制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022758A (en) * 1973-06-19 1977-05-10 Ab Kabi Isolation of coagulation factors I and VIII from biological material
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US20050227929A1 (en) 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
US20080125580A1 (en) * 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
ES2516694T3 (es) * 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US7696171B1 (en) 2006-11-09 2010-04-13 The Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
CA2796459C (en) * 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
US9714291B2 (en) * 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
EP3419599A4 (en) * 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
EP4621067A3 (en) * 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN111315886A (zh) * 2017-06-23 2020-06-19 珠海亿胜生物制药有限公司 重组人碱性成纤维细胞生长因子(rh-bFGF)以及包含rh-bFGF的药物组合物
US11103552B2 (en) * 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2023532046A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)